Centers for Advanced Research Research & Impact Centers for Advanced ResearchAPDA Centers for Advanced Research received $800,000 in funding in 2018.The Centers support large research programs which include: research trainees; fellowship programs; early stage discovery programs and later stage clinical translation. These Centers facilitate research which is at the forefront investigations in the causes, treatments and ultimately finding the cure(s) for Parkinson’s disease. University of Alabama at Birmingham, School of MedicineDavid G. Standaert, MD, PhD, DirectorAPDA funding supports:Studies of neuroinflammation, protein aggregation and oxidative stress in PD as well as the role of the microbiomeMultiple clinical trials including those testing novel drugs, DBS techniques and exercise interventionAn active DBS program with approximately 150 procedures performed per yearApproximately 6800 patient visits per year Brigham and Women’s Hospital, Harvard Medical SchoolClemens Scherzer, MD, DirectorAPDA funding supports:Studies that probe the biology of PD-causing genetic mutationsA biomarker discovery program using specimens from more than 2,700 participantsA drug discovery program that utilizes technologies such as stem cells and big data analyticsApproximately 2,200 patients visits each year Emory University School of MedicineThomas Wichmann, MD, Interim DirectorAPDA funding supports:Studies aimed at understanding the brain pathways involved in PDClinical trials investigating treatments for wearing off, hallucinations, low blood pressure, daytime sleepiness and dementiaAn active DBS program and approximately 80-100 procedures performed per yearApproximately 14, patient visits per year Boston University School of MedicineMarie Hélène Saint-Hilaire, MD, FRCP (C), DirectorAPDA funding supports:Studies to identify potential PD biomarkersCharacterization of PD among various ethnic groupsExercise intervention, wearable technology and attention training clinical trialsApproximately 4000 patient visits per year Washington University School of MedicineJoel S. Perlmutter, MD, DirectorAPDA funding supports:Studies of genetic and environmental risk factors of PDDrug development for neuroprotection in PDAn active DBS program with 75-100 procedures performed yearlyApproximately 6,500 patient visits each year Rutgers Robert Wood Johnson Medical SchoolM. Maral Mouradian, MD, Interim DirectorAPDA funding supports:Studies of levodopa induced dyskinesias, DBS optimization and neuroprotectionMultiple clinical trials including ones for Progressive Supranuclear PalsyAn active DBS program with 75-100 procedures performed per yearApproximately 4,200 patient visits per year University of Pittsburgh Medical CenterJ. Timothy Greenamyre, MD, PhD, DirectorAPDA funding supports:Studies of molecular and biochemical causes of PD and the interaction between genetic and environmental factors in causing PDGene therapy clinical trialsAn active DBS program with approximately 70 procedures performed per yearApproximately 3,000 patient visits per yearMayo Clinic, JacksonvilleDennis Dickson, MD, DirectorAPDA funding supports:Studies to identify novel gene mutations that contribute to ParkinsonismA range of clinical trials from gait in advanced PD to Lewy bodies of the gutA very active DBS program with 75-100 procedures performed per yearApproximately 1,500 patients seen each yearShare this page:
